5
Registered trials
2
Recruiting
4
Unique sponsors
9
Unique IMPs
4
Commercial trials
Drug classes (ATC)
—
ATC code not specified
3
L
Oncology (ATC L)
2
N
Neurology/Psychiatry (ATC N)
1
V
Various (ATC V)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Checkpoint inhibitor (PD-1)
1 substance
Antibody-drug conjugate (ADC)
1 substance
Macrolide / aminoglycoside
1 substance
Antimetabolite
1 substance
Topoisomerase I inhibitor
1 substance
Platinum compound
1 substance
Phase II:
4
Phase I:
1
Phase II
4 trials-
EndedBoehringer Ingelheim International GmbH Commercial(3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID
-
RecruitingCebiotex S.L. Commercial7-ETHYL-10-HYDROXYCAMPTOTHECIN
-
EndedSeagen Inc. CommercialPEMBROLIZUMAB; TISOTUMAB VEDOTIN
-
RecruitingIRCCS Istituto Nazionale Tumori Fondazione Pascale AcademicBLEOMYCIN SULFATE; CALCIUM LEVOFOLINATE; FLUOROURACIL; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN
Phase I
1 trial-
HaltedSeagen Inc. CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Seagen Inc. | Commercial | 2 | Phase I, Phase II | 0 |
| Boehringer Ingelheim International GmbH | Commercial | 1 | Phase II | 0 |
| Cebiotex S.L. | Commercial | 1 | Phase II | 1 |
| IRCCS Istituto Nazionale Tumori Fondazione Pascale | Academic | 1 | Phase II | 1 |
New trials by year
2019
1
2022
1
2024
3